Two-week dosing lowers severe side effects in PRABITAS
PRABITAS tested a two-week schedule of trifluridine-tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer. In the comparison of 970 people, the simpler schedule met the prespecified criterion for non-inferior overall survival and was linked to less severe neutropenia than conventional dosing. It did not establish superior survival. The trial was conducted in Japan, and its full safety findings matter when judging which patients may benefit from a different schedule.
Science··Morning
A new schedule for the same medicines
PRABITAS compared two schedules for trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer. The analysed population numbered 970 in the Japanese trial. Rather than introducing a new medicine, investigators tested a simpler 14-day arrangement against conventional 28-day dosing of the same combination. Tolerability can matter greatly after several lines of treatment. The study addressed this practical issue alongside its principal question about preserving overall survival.[1], [2]
Survival met the non-inferiority test
Median overall survival was 11.3 months under the simplified schedule and 10.3 months under conventional dosing. The 14-day arrangement met the prespecified statistical test for non-inferior overall survival. It did not demonstrate superior survival. The numerical difference between the two medians alone cannot justify that stronger claim. This pragmatic study allowed flexibility in dose modification and chemotherapy timing, reflecting aspects of ordinary care.[1], [2]
Severe neutropenia declined
Grade 3 or worse neutropenia occurred in 13% of the simpler-schedule group and 39% under conventional dosing. Other severe blood-cell problems and effects such as anorexia, nausea and diarrhoea were less frequent. Dose reductions and treatment delays also declined. Quality-of-life data were not presented at the congress, however. Fewer adverse events are not direct proof of improved daily life, and applicability in other clinical settings needs separate assessment.[1], [2]
